media – Page 137 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Medical Fair China 2024

Organiser:Messe Düsseldorf Time:21- 23 August 2024 address：No. 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou City Exhibition hall: Suzhou International Expo Centre, China Product range: Hospital facilities and equipment: Medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, disposable medical supplies, dressings and hygiene materials, all kinds of surgical instruments Hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, beds, operating tables, operating table spotlights, inspection Check the bed, gums and all kinds of hospital furniture Medical care equipment: all kinds of medical and home rehabilitation physiotherapy products About CDMEE： Jiangsu Suzhou Medical Device Innovation Exhibition (Medical Fair China) with the theme of “smart health”, directly and comprehensively serving the medical device industry from the source to the terminal of the entire medical industry chain. Gather advanced medical technology products at ...
- Source: drugdu
- 178
- May 17, 2024
New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections

Until now, researchers and clinicians have lacked diagnostic tools to easily differentiate between past infections with different flaviviruses—a family of mostly mosquito- and tick-borne viruses that include Zika and dengue. This challenge has hindered clinical-epidemiologic studies, viral diagnostics, and vaccine development. Antibodies for Zika virus, a mosquito-borne virus that spread to the Americas in 2015 and continues to cause sporadic outbreaks, can often be mistaken for dengue virus antibodies in many diagnostic tests. This confusion makes it difficult to determine if a person who tests positive had dengue, Zika, or both. For reproductive-age women, it is particularly crucial to know if they have had Zika and likely have immunity since infection during pregnancy can lead to birth defects. Knowing their immunity status can guide their efforts to avoid mosquito bites in endemic areas during pregnancy. Now, a newly discovered Zika virus-specific synthetic molecule can distinguish Zika-immune patient samples from those ...
- Source: drugdu
- 100
- May 16, 2024
New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several hundred thousand hospitalizations and as many as 51,000 deaths. Syndromic testing systems have improved the detection of co-infections, thus reducing the need for further testing. These systems provide rapid results, enabling healthcare providers to make timely decisions and stop unnecessary antibiotic treatments when viral pathogens are identified, which helps reduce antibiotic use and supports responsible antimicrobial stewardship. A new respiratory syndromic testing panel now allows for the accurate diagnosis of respiratory infections and the detection of co-infections. This panel delivers results in about one hour and requires less than one minute of hands-on time, while providing easy access to cycle threshold (Ct) values and amplification curves. QIAGEN N.V. (Venlo, the Netherlands) has received clearance from the U.S. Food and Drug ...
- Source: drugdu
- 98
- May 16, 2024
Results from FRONTIER 2 Trial Show Promise of Mim8 as a Potential Treatment for Hemophilia A

Don Tracy, Associate Editor In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes. Novo Nordisk announced successful results from the Phase IIIa FRONTIER 2 trial, which evaluated the efficacy and safety of Mim8, a promising new treatment for hemophilia A. According to the company, this trial enrolled 254 participants over the age of 12 years to analyze the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment. The trial met its two primary endpoints, which were to demonstrate significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly administration of Mim8.1 “We are very pleased with the positive results from the FRONTIER 2 clinical trial. These data demonstrate the ability of Mim8 to prevent bleeding episodes effectively and safely in people with ...
- Source: drugdu
- 110
- May 16, 2024
AbbVie, Gilgamesh Pharmaceuticals Agree to Terms on a Collaboration to Develop Advanced Therapies for Psychiatric Disorders

The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.AbbVie and Gilgamesh Pharmaceuticals have announced a partnership focused on the development of therapies for psychiatric disorders. The collaboration seeks to leverage AbbVie’s experience in psychiatry and Gilgamesh’s research platform that focuses on neuroplastogens, which works to treat psychiatric conditions while minimizing adverse effects attributed to psychedelic compounds. According to the companies, the overall goal is to provide new opportunities in areas that haven’t provided manysolutions for patients with mood and anxiety disorders through the use of neuroplastogens. Under terms of the deal, AbbVie is expected to focus on future development and commercialization activities, while Gilgamesh will receive $65 million as an upfront payment. Upon the completion of specific milestones, including option fees and tiered royalties on net sales, Gilgamesh could potentially receive up to $1.95 billion.1 “Significant unmet need remains for ...
- Source: drugdu
- 120
- May 16, 2024
BBSRC invests £48m in Babraham Institute to advance lifelong health research

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability to protect health and counter age-related decline, including cellular response to stress, epigenetic control across the life course, immunity, resilience and repair. In close collaboration with partners across academia, including the BBSRC’s other strategically supported research institutes and companies based on the Babraham Research Campus, the research will be delivered ...
- Source: drugdu
- 112
- May 16, 2024
MIT’s new MRI brain light-detecting technique could support brain cell studies

Engineers from the Massachusetts Institute of Technology (MIT) have developed a new technique using magnetic resonance imaging (MRI) to detect light deep in the brain, which could benefit future studies of the development and communication of brain cells. Published in Nature Biomedical Engineering, the new technique could help researchers explore the inner workings of the brain, such as changes in gene expression, anatomical connections between cells or how cells communicate with each other. Commonly, scientists label cells with bioluminescent proteins that glow to allow them to track the growth of a tumour or measure changes in gene expression that occur as cells differentiate. Known as bioluminescence, the novel technique uses MRI to observe the dilation of a protein in the brain’s blood vessels to pinpoint the source of light. The team came up with a method to transform the blood vessels of the brain into light detectors to find a ...
- Source: drugdu
- 80
- May 16, 2024
Hengrui Pharmaceuticals Innovative Drug SHR-2173 Injection for IgA Nephropathy Indication Approved for Clinical Use

Recently, Hengrui Pharmaceuticals’ subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving SHR-2173 Injection, a Class 1 new drug, to carry out clinical trials for IgA nephropathy. At present, there is no similar drug to SHR-2173 on the market or in the clinical development stage at home and abroad. IgA nephropathy is a group of autoimmune glomerulonephritis characterized by IgA deposition in the glomerular mesangial area. Typical clinical manifestations can be seen in microscopic hematuria, and patients have a history of mucosal (e.g., upper respiratory tract, gastrointestinal tract) infections, which is the most common primary glomerulopathies worldwide, and also a major cause of chronic kidney disease (CKD) and renal failure. In China, IgA nephropathy accounts for 45% of primary glomerular diseases in China. There are geographical differences in the incidence of the disease, and the peak ...
- Source: drugdu
- 84
- May 16, 2024
First Patient Dosed in Phase I Clinical Trial of Degu Insulin Liraglutide Injection

Tong Hua Dong Bao Pharmaceutical Co., Ltd (hereinafter referred to as the “Company”) has initiated the Phase I clinical trial in China after receiving the notification of approval for the clinical trial of Degu Insulin Liraglutide Injection from the State Drug Administration and has recently successfully completed the first case of patient dosing. The completion of Phase I clinical trial of Degu Insulin Liraglutide Injection is another significant progress in the development of GLP-1RA compound formulation of insulin analog, which will further enhance the competitiveness of the Company in the field of endocrine therapy. In the future, the Company is expected to accelerate the process of clinical trials and speed up the approval and listing of its products by virtue of its R&D advantages accumulated in the field of diabetes treatment over the years, so as to provide richer and better choices for clinical medication. Degu Insulin Liraglutide Injection has ...
- Source: drugdu
- 87
- May 16, 2024
【EXPERT Q&A】What does the 4-digit number next to the CE mark on medical devices mean?

Drugdu.com expert’s response: The 4-digit number next to the CE mark on medical devices indicates the Notified Body identification number (or Module D number). These digits identify the Notified Body that has certified the device’s quality management system. It signifies the registration number of the certifying body, indicating that it has assessed the quality management system of the medical device and confirmed its compliance with the relevant European Union directive requirements. This number is crucial for tracking the validity of the certification and for regulatory purposes.
- Source: drugdu
- 157
- May 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.